作为曾与华熙生物、爱美客齐名的国内“医美三剑客”之一,昊海生科凭借A+H双融资平台的资本优势及在医美、眼科等高景气赛道的布局,一度成为市场瞩目的明星企业。然而眼下,与其昔日光环相伴的,是核心业务增长引擎集体失速,为寻求突围而进行的并购交易疑窦丛生,公司治理层面问题频发等。业绩全面失速仍慷慨分红 控股股东成最大受益者从业绩表现看,公司营收与净利润已连续多个季度同比下滑。2025年前三季度,公司实现...
Source Link作为曾与华熙生物、爱美客齐名的国内“医美三剑客”之一,昊海生科凭借A+H双融资平台的资本优势及在医美、眼科等高景气赛道的布局,一度成为市场瞩目的明星企业。然而眼下,与其昔日光环相伴的,是核心业务增长引擎集体失速,为寻求突围而进行的并购交易疑窦丛生,公司治理层面问题频发等。业绩全面失速仍慷慨分红 控股股东成最大受益者从业绩表现看,公司营收与净利润已连续多个季度同比下滑。2025年前三季度,公司实现...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.